Payment overview · 2025
General Payments
$582.91
33 reported records · 10 companies
Healthcare provider profile · identity verified
Tammy Leong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BIRMINGHAM, AL · NPI 1477615425
Verified facts
What the public records show
CMS Open Payments records show Tammy Leong, M.D. received $582.91 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.73 | 28.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.49 | 27.7% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.74 | 13.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.07 | 12.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.10 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.70 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.97 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.26 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.43 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.42 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $582.91 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $152.66 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $152.66 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.60 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.74 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.74 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $74.13 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.31 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $8.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 107 |
| Gabapentin | Gabapentin | 267 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 95 |
| Alprazolam | Alprazolam | 212 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 70 |
| Trazodone Hcl | Trazodone Hcl | 174 | 52 |
| Losartan Potassium | Losartan Potassium | 169 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 51 |
| Montelukast Sodium | Montelukast Sodium | 166 | 56 |
| Clonazepam | Clonazepam | 163 | 31 |
| Lisinopril | Lisinopril | 152 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 50 |
| Mounjaro | Tirzepatide | 131 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 42 |
| Tramadol Hcl | Tramadol Hcl | 122 | 32 |
| Metformin Hcl Er | Metformin Hcl | 120 | 36 |
| Lorazepam | Lorazepam | 118 | 23 |
| Meloxicam | Meloxicam | 110 | 39 |
| Furosemide | Furosemide | 103 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 39 |
| Metformin Hcl | Metformin Hcl | 93 | 26 |
| Famotidine | Famotidine | 90 | 35 |
| Glimepiride | Glimepiride | 90 | 31 |
| Bupropion Xl | Bupropion Hcl | 89 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 24 |
| Eliquis | Apixaban | 77 | 20 |
| Jardiance | Empagliflozin | 77 | 13 |
| Buspirone Hcl | Buspirone Hcl | 76 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 28 |
| Celecoxib | Celecoxib | 73 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 21 |
| Methylprednisolone | Methylprednisolone | 70 | 64 |
| Potassium Chloride | Potassium Chloride | 70 | 20 |
| Simvastatin | Simvastatin | 70 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 27 |
| Omeprazole | Omeprazole | 68 | 29 |
| Ozempic | Semaglutide | 68 | 18 |
| Allopurinol | Allopurinol | 64 | 20 |
| Synthroid | Levothyroxine Sodium | 64 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 29 |
| Donepezil Hcl | Donepezil Hcl | 58 | 14 |
| Sertraline Hcl | Sertraline Hcl | 58 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 14 |
| Valsartan | Valsartan | 55 | 21 |
| Valacyclovir | Valacyclovir Hcl | 53 | 25 |
| Mirtazapine | Mirtazapine | 52 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 18 |
| Atenolol | Atenolol | 49 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Baclofen | Baclofen | 46 | 22 |
| Januvia | Sitagliptin Phosphate | 44 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 44 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 18 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Spironolactone | Spironolactone | 38 | 15 |
| Carvedilol | Carvedilol | 37 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 35 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 12 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 12 |
| Risedronate Sodium | Risedronate Sodium | 33 | 11 |
| Estradiol | Estradiol | 32 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Ramipril | Ramipril | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $582.91 · 33 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, FREESTYLE LIBRE 3, KRYSTEXXA, Kerendia, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error